A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: Opening a closed book

Biological Psychiatry

Volumn 55, Issue 10, 2004, Pages 1013-1022

  Mishara, Aaron L ^a   Goldberg, Terry E ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Antipsychotic; meta analysis; neuroleptic; neuropsychology; schizophrenia

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; THIORIDAZINE;

ATTENTION; BRAIN BLOOD FLOW; COGNITION; DATA BASE; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; EYE MOVEMENT CONTROL; HUMAN; INFORMATION PROCESSING; MEMORY; MENTAL PATIENT; MENTAL TEST; MOTOR PERFORMANCE; NEGATIVE SYNDROME; OUTCOMES RESEARCH; PATIENT CODING; PERCEPTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SAMPLE SIZE; SCHIZOPHRENIA; STATISTICAL ANALYSIS; TIME PERCEPTION; TREATMENT OUTCOME;

EID: 2342475885     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2004.01.027     Document Type: Article

References (108)

1. Allain H., Schueck S., Maduit N., Djemai M. Comparative effects of pharmacotherapy on the maintenance of cognitive function. Eur Psychiatry. 16:(suppl 1):2001;35s-41s
2. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia. 1997;American Psychiatric Association, Washington, DC
3. Angel H.V. Role of chlorpromazine in maintaining timing behavior in schizophrenics. Psychopharmocologica. 28:1973;185-194
4. Baker R.R. The effects of psychotropic drugs on psychological testing. Psychol Bull. 69:1968;377-387
5. Barch D.M., Cohen J.D., Servan-Schreiber D., Steingard S., Steinhauer S.S., van Kammen D.P. Semantic priming in schizophrenia An examination of spreading activation using word pronunciation and multiple SOA's. J Abnorm Psychol. 105:1996;592-601
6. Bedard M.A., Scherer H., Delorimier J., Stilp E., Lalonde P. Differential effects of D-2 and D-4 blocking neuroleptics on the procedural learning of schizophrenic patients. Can J Psychiatry. 41:(1 suppl):1996;21S-24S
7. Bilder R.M., Turkel E., Lipschutz-Broch L., Lieberman J.A. Antipsychotic medication effects on neuropsychological functions. Psychopharmacol Bull. 28:1992;353-366
8. Blyler C.R., Gold J.M. Cognitive effects of typical antipsychotic treatment Another look. Sharma T., Harvey P. Cognition in Schizophrenia, Impairments, Importance and Treatment Strategies. 2000;241-285 Oxford University Press, New York
9. Bollini P., Pampallona S., Orza M.J., Adams M.E., Chalmers T.C. Antipsychotic drugs Is more worse? A meta-analysis of the published randomized control trials. Psychol Med. 24:1994;307-316
10. Borenstein M., Rothstein H. Comprehensive Meta-Analysis A Computer Program for Research Synthesis. 1999;Biostat, Englewood, New Jersey
11. Braff D.L., Saccuzzo D.P. Effect of antipsychotic medication on speed of information processing in schizophrenic patients. Am J Psychiatry. 139:1982;1127-1130
12. Breier A., Schreiber J.L., Dyer J., Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Arch Gen Psychiatry. 48:1991;239-246
13. Calev A. Recall and recognition in mildly disturbed schizophrenics The use of matched tasks. Psychol Med. 14:1984;425-429
14. Callaway E. Schizophrenia and inference. An analogy with a malfunctioning computer. Arch Gen Psychiatry. 22:1970;193-208
15. Cassens G., Inglis A.K., Appelbaum P.S., Gutheil T.G. Neuroleptics Effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull. 16:1990;477-499
16. Chapman L., Chapman J. Disordered Thought in Schizophrenia. 1973;Appleton-Century-Crofts, New York
17. Cleghorn J.M., Kaplan R.D., Szechtman B., Szetchman H., Brown G.M. Neuroleptic drug effects on cognitive function in schizophrenia. Schizophr Res. 3:1990;211-219
18. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed:1988;Academic Press, New York
19. Crawford T.J., Haeger B., Kennard C., Reveley M.A., Henderson L. Saccadic abnormalities in psychotic patients II. The role of neuroleptic treatment. Psychol Med. 25:1995;473-483
20. Curtin F., Elbourne D., Altman D.G. Meta-analysis combining parallel and cross-over clinical trials, III The issue of carry-over. Stat Med. 21:2002;2161-2173
21. Daston P.G. Effects of two phenothiazine drugs on concentrative attention span of chronic schizophrenics. J Clin Psychol. 15:1959;106-109
22. DerSimonian R., Laird N.M. Meta-analysis in clinical trials. Control Clin Trials. 7:1986;177-188
23. Drachman D.A. Memory and the cholinergic system. Fields W.S. Neurotransmitter Function. 1978;Yearbook Publishers, New York
24. Dunlap W.P., Cortina J.M., Vaslow J.B., Burke M.J. Meta-analysis of experiments with matched groups or repeated measures designs. Psychol Methods. 1:1996;170-177
25. Duval S., Tweedie R. Trim and fill A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 56:2000;455-463
26. Egger M., Smith G.D., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 315:1997;629-634
27. Eitan N., Levin Y., Ben-Artzi E., Levy A., Neuman M. Effects of antipsychotic drugs on memory functions of schizophrenic patients. Acta Psychiatr Scand. 85:1992;74-76
28. Erickson W.D., Yellin A.M., Hopwood J.H., Realmuto G.M., Greenberg L.M. The effects of neuroleptics on attention in adolescent schizophrenics. Biol Psychiatry. 19:1984;745-753
29. Elvevåg B., Goldberg T.E. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol. 14:2000;1-21
30. Faustman WO, Hoff AL (1996): Effects of antipsychotic drugs on neuropsychological measures. In: Csernasky JG, editor. Handbook of Experimental Pharmacology, Vol. 120. Berlin: Springer Verlag, 445-471
31. Flekkoy K. Changes in associative performance in hospitalized schizophrenics A sixteen-year follow-up. Acta Psychiatr Scand. 52:1975;330-335
32. Flekkoy K, Astrup C, Hartmann (1969): Word associations in schizophrenics: A ten-year follow-up. Acta Psychiatr Scand 45:209-216
33. Frith C.D. Schizophrenia, memory, and anticholinergic drugs. J Abnorm Psychol. 93:1984;339-341
34. Galbraith R. A note on graphical representation of estimated odds ratios from several clinical trials. Stat Med. 7:1988;889-894
35. Geddes J., Freemantle N., Harrison P., Bebbington P. Atypical antipsychotics in the treatment of schizophrenia Systematic overview and meta-regression analysis. BMJ. 321:2000;1371-1376
36. Gilbertson M.W., van Kammen D.P. Recent and remote memory dissociation Medication effects and hippocampal function in schizophrenia. Biol Psychiatry. 42:1997;585-595
37. Gilgash C.A. Effects of thorazine on Wechsler scores of adult catatonic schizophrenics. Psychol Rep. 3:1957;561-564
38. Glass G.V., McGaw B., Smith M.L. Meta-Analysis in Social Research. 1981;Sage Publications, Beverly Hills
39. Goldberg T.E., Gold J.M. Neurocognitive functioning in patients with schizophrenia An overview. Bloom F.E., Kupfer D.J. Psychopharmacology The Fourth Generation of Progress. 1995;1245-1257 Raven Press, New York
40. Goldberg T.E., Green M.F. Neurocognitive functioning in patients with schizophrenia An overview. Davis K.L., Charney D., Coyle J.T., Nemeroff C. Neuropsychopharmacology The Fifth Generation of Progress. 2002;657-669 Lippincott Williams & Wilkins, Philadelphia
41. Goldberg T.E., Greenberg R.D., Griffin S.J. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry. 162:1993;43-48
42. Goldberg T.E., Weinberger D.R. Effects of neuroleptic medications on the cognition of patients with schizophrenia A review of recent studies. J Clin Psychiatry. 57:1996;62-65
43. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 153:1996;321-330
44. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits in schizophrenia Are we measuring the right stuff? Schizophr Bull. 26:2000;119-126
45. Green M.F., Marder S.R., Glynn S.M., McGurk S.R., Wirshing W.C., Liberman R.P., Mintz J. The neurocognitive effects of low-dose haloperidol A two year comparison with risperidone. Biol Psychiatry. 51:2002;972-978
46. Green M.F., Marshall B.D. Jr, Wirshing W.C., Ames D., Marder S.R., McGurk S., et al. Does risperidone improve working memory in treatment-resistant schizophrenia? Am J Psychiatry. 154:1997;799-804
47. Hagger C., Buckley P., Kenny J.T., Friedman L., Ubogy D., Meltzer H.Y. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry. 34:1993;702-712
48. Harris M.J., Heaton R.K., Schalz A., Bailey A., Patterson T.L. Neuroleptic dose reduction in older patients. Schizophr Res. 27:1997;241-248
49. Hartlage L.C. Effects of chlorpromazine on learning. Psychol Bull. 64:1965;235-245
50. Harvey P.D., Davidson M., Muesser K.T., Parrella M., White L., Powchick P. Social adaptive functioning evaluation (SAFE) A rating scale for geriatric patients. Schizophr Bull. 23:1997;131-139
51. Harvey P.D., Moriarty P.J., Serper M.R., Schnur E., Lieber D. Practice-related improvement information processing with novel antipsychotic treatment. Schizophr Res. 46:2000;139-148
52. Harvey P.D., Keefe R.S.E. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry. 158:2001;176-184
53. Heaton R.K., Crowley T.J. Effects of psychiatric disorders and their somatic treatments on neuropsychological test results. Filskov S.D., Boll T.J. Handbook of Clinical Neuropsychology. 1981;481-525 John Wiley & Sons, New York
54. Hedges L.V., Olkin I. Statistical Methods for Meta-Analysis. 1985;Academic Press, Orlando, Florida
55. Heinrichs R.W., Zakzanis K. Neurocognitive deficit in schizophrenia A quantitative review of the evidence. Neuropsychology. 12:1998;426-445
56. Holzman P.S. Perceptual aspects of psychopathology. Zubin J., Shagass C. Neurobiological Aspects of Psychopathology. 1969;Grune & Strutton, New York
57. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J.M., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials Is blinding necessary? Control Clinical Trials. 17:1996;1-12
58. Johnson BT (1989): D-STAT: Software for the Meta-Analytic Review of Research Literatures. Hillsdale, New Jersey: Lawrence Earlbaum
59. Joober R, Rouleau GA, Lal S, Dixon M, O'Driscoll, Palmour R, et al (2002): Neuropsychological impairments in neuroleptic-responder vs. -nonresponder schizophrenic patients and healthy volunteers. Schizophr Res 53:229-138
60. Kahn K.S., Daya S., Jadd A.R. The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med. 156:1996;661-666
61. Kapur S., Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry. 158:2001;360-369
62. Kapur S., Zipursky R., Jones C., Remington G., Houle S. Relationship between dopamine (D2) occupancy, clinical response, and side effects A double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 157:2000;514-520
63. Keefe R.S., Silva S.G., Perkins D.O., Lieberman J.A. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia A review and meta-analysis. Schizophr Bull. 25:1999;201-222
64. Kern R.S., Green M.F., Marshall B.D., Wirshing W.C., Wirshing D., Lieberman J.A. Risperidone vs. haloperidol on secondary memory Can newer antipsychotics aid learning? Schizophr Bull. 25:1999;223-233
65. Killian G.A., Holzman P.S., Davis J.M., Gibbons R. Effects of psychotropic medication on selected cognitive and perceptual measures. J Abnorm Psychol. 93:1984;58-70
66. King D.J. The effect of neuroleptics on cognitive and psychomotor function. Br J Psychiatry. 157:1990;799-811
67. Kite M.E., Johnson B.T. Attitudes toward older and younger adults A meta-analysis. Psychol Aging. 3:1988;233-244
68. Kornetsky C. The use of a simple test of attention as a measure of drug effects in schizophrenic patients. Psychopharmalogica. 24:1972;99-106
69. Kraeplin E (1919/1971): Dementia Praecox and Paraphrenia [Barclay RM, Krieger RE, translators]. New York: Huntington
70. Lee M.A., Jayathilake K., Meltzer H.Y. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in the neuroleptic responsive schizophrenic. Schizophr Res. 37:1999;1-11
71. Lehman A.F., Steinwachs D.M. Patterns of usual care for schizophrenia Initial results from the schizophrenia patient outcomes research team (PORT) client survey. Schizophr Bull. 24:1998;11-20
72. Levine J., Caspi N., Laufer N. Immediate effects of chlorpromazine and perphenazine following neuroleptic washout on word association of schizophrenic patients. Schizophr Res. 26:1997;55-63
73. Lezak M.D. Neuropsychological Assessment. 3rd ed:1995;Oxford University Press, New York
74. Light R.J., Pillemer D.B. Summing Up The Science of Reviewing Research. 1984;Harvard University Press, Cambridge, Massachusetts
75. Lipsey M.W., Wilson D.B. Practical Meta-Analysis. 2001;Sage Publications, Thousand Oaks, California
76. Marder S.R., Asarnow R.F., van Puten T. Information processing and neuroleptic response in acute and stabilized schizophrenic patients. Psychiatry Res. 13:1984;41-49
77. Medalia A., Gold J.M., Merriam A. The effects of neuroleptics on neuropsychological test results of schizophrenics. Arch Clin Neuropsychol. 3:1988;249-271
78. Mirsky A.F., Kornetsky C. On the dissimilar effects of drugs on the Digit Symbol Substitution and Continuous Performance Tests. Psychopharmacologia. 5:1964;161-177
79. Moher D., Cook D.J., Jadad A.R., Tugwell P., Moher M., Jones A., et al. Assessing the quality of reports of randomized trials Implications for the conduct of meta-analyses. Health Technol Assess. 3:1999;1-98
80. Morris S.B., DeShon R.P. Combining effect size estimates in meta-analysis with repeated measures and independent-groups designs. Psychol Methods. 7:2002;105-125
81. Mortimer A.M. Cognitive function in schizophrenia - do neuroleptics make a difference? Pharmacol Biochem Behav. 56:1997;789-795
82. Oltmanns T.F., Ohayon J., Neale J.N. The effect of antipsychotic medication and diagnostic criteria on distractibility in schizophrenia. J Psychiatry Res. 14:1978;81-91
83. Orzack M.H., Kornetsky C., Freeman H. The effects of daily administration of carphenazine on attention in the schizophrenic patient. Psychopharmalogica. 11:1967;31-38
84. Perlick D., Stansky P., Katz I., Mayer M., Mattis S. Memory deficits and anticholinergic levels in chronic schizophrenia. Am J Psychiatry. 143:1986;230-232
85. Pigache R.M., Norris H. Selective attention as an index of the antipsychotic action of chlorpromazine in schizophrenia. Bull Br Psychol Soc. 26:1973;160
86. Potkin S.G., Fleming K., Jin Y., Gulasekarum B. Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. J Clin Psychopharmacol. 21:2001;479-483
87. Pugh L.A. Response time and electrodermal measures in chronic schizophrenia The effects of chlorpromazine. J Nerv Ment Dis. 146:1968;62-70
88. Rappaport M., Rogers N., Reynolds S., Weinmann R. Comparative ability of normal and schizophrenic subjects to attend to competing voice messages Effects of method of presentation, message load and drugs. J Nerv Ment Dis. 143:1966;16-27
89. Reich B. Moderne Schizophreniebehandlung, Verbesserung der kognitiven Funktionen [Modern treatment for schizophrenia, improvement of cognitive functions]. Fundamenta Psychiatrica. 2:2001;51-53
90. Rollnik J.D., Borsutzky M., Huber T.J., Mogk H., Seifert J., Emrich H.M., Schneider U. Short-term cognitive improvement in schizophrenics treated with typical and atypical neuroleptics. Neuropsychobiology. 45:2002;74-80
91. Salo R., Robertson L.C., Nordahl T.E., Kraft L.W. The effects of antipsychotic medication on sequential inhibitory processes. J Abnorm Psychol. 106:1997;639-643
92. Schulz K.F., Chalmers I., Hayes R.J., Altman D.G. Empirical evidence of bias, dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 273:1995;408-412
93. Spiegal D.E., Keith-Spegal P. The effects of carphenazine, trifluoperazine and chlorpromazine on ward behavior, physiologic functioning and psychological test scores in chronic schizophrenic patients. J Nerv Ment Dis. 144:1967;111-116
94. Spohn H.E., Coyne L., LaCoursiere R., Mazur D., Hayes K. Relation of neuroleptic dose and tardive dyskinesia to attention, information-processing, and psychophysiology in medicated schizophrenics. Arch Gen Psychiatry. 34:1977;633-644
95. Spohn H.E., Coyne L., LaCoursiere R., Mazur D., Hayes K. Relation of neuroleptic treatments on attention, information processing, and psychophysiology in medicated schizophrenics. Psychopharmacol Bull. 21:1985;582-587
96. Spohn H.E., Strauss M.E. Relation of neuroleptic and anticholinergic medication to cognitive functions of schizophrenia. J Abnorm Psychol. 98:1989;367-380
97. Stone GC, Callaway E, Jones RT, Gentry T (1969): Chlorpromazine slows decay of visual short term memory. Psychonom Sci 16:229-230
98. Strauss M.E., Lew M.F., Coyle J.T., Tune L.E. Psychopharmacologic and clinical correlates of attention and chronic schizophrenia. Am J Psychiatry. 4:1985;497-499
99. Strauss ME, Reynolds KA, Tune (1990): Effects of anticholinergic medication on memory in schizophrenia. Schizophr Res 3:127-129
100. Sweeney J.A., Keilp J.G., Haas G.L., Hill J., Weiden P.J. Relationships between medication treatments and neuropsychological test performance in schizophrenia. Psychiatr Res. 37:1991;297-308
101. Tamlyn D., McKenna P.J., Mortimer A.M., Lund C.E., Hammond C., Baddeley A.D. Memory impairment in schizophrenia Its extent, affiliations and neuropsychological character. Psychol Med. 22:1992;101-115
102. Thornley B., Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ. 317:1998;181-184
103. Tune L.E., Straus M.E., Lew M.F., Breitlinger E., Coyle J.T. Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenia patients. Am J Psychiatry. 139:1982;1460-1462
104. Vaiva G., Thomas P., Llorca P.M., Dupont S., Cottencin O., Devos P., et al. SPECT imaging, clinical features, and cognition before and after low doses of amisulpride in schizophrenic patients with the deficit syndrome. Psychiatry Res. 115:2002;37-48
105. Weickert T.W., Goldberg T.E., Marenco S., Bigelow L.B., Egan M.F., Weinberger D.R. Comparison of cognitive performances during placebo period and an atypical antipsychotic treatment period in schizophrenia Critical examination of confounds. Neuropsychopharmacology. 28:2003;1491-1500
106. Wolfram Research (2002): Mathematica, Version 4.2. Champaign, Illinois: Wolfram Research
107. Zahn T.P., Pickar D., Haier R.J. Effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia. Schizophr Res. 13:1994;133-144
108. Zakzanis K.K. Statistics to tell the whole truth, and nothing but the truth Formulae, illustrative numerical examples, and heuristic interpretation of effect size analyses for neuropsychological researchers. Arch Clin Neurol. 16:2000;653-667